Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-11-17 4:22 pm Purchase | 2025-11-13 | 13D | Marker Therapeutics, Inc. MRKR | New Enterprise Associates 16, L.P. | 1,670,081 9.900% | 44,403 (+2.73%) | Filing History |
| 2025-11-14 8:08 pm Purchase | 2025-09-30 | 13G | Marker Therapeutics, Inc. MRKR | Alyeska Investment Group, L.P. | 1,280,952 9.900% | 211,293 (+19.75%) | Filing History |
| 2025-08-20 4:58 pm Sale | 2025-08-19 | 13D | Marker Therapeutics, Inc. MRKR | John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 | 641,801 4.960% | -18,100 (-2.74%) | Filing History |
| 2025-08-19 2:42 pm Sale | 2025-08-15 | 13D | Marker Therapeutics, Inc. MRKR | John R. Wilson TTE, John R. Wilson Revocable Trust U/A DTD 08/03/2017 | 659,901 5.100% | -166,284 (-20.13%) | Filing History |
| 2025-08-18 5:34 pm Unchanged | 2025-08-14 | 13D | Marker Therapeutics, Inc. MRKR | New Enterprise Associates 16, L.P. | 1,625,678 12.600% | 0 (Unchanged) | Filing History |
| 2025-05-15 4:13 pm Purchase | 2025-03-31 | 13G | Marker Therapeutics, Inc. MRKR | Blue Owl Capital Holdings LP | 1,127,052 9.990% | 572,802 (+103.35%) | Filing History |
| 2025-02-14 5:09 pm Purchase | 2024-12-31 | 13G | Marker Therapeutics, Inc. MRKR | Blue Owl Capital Holdings LP | 554,250 5.180% | 554,250 (New Position) | Filing History |
| 2025-02-14 4:26 pm Purchase | 2024-12-31 | 13G | Marker Therapeutics, Inc. MRKR | Alyeska Investment Group, L.P. | 1,069,659 9.990% | 1,069,659 (New Position) | Filing History |
| 2024-12-23 4:30 pm Purchase | 2024-12-19 | 13D | Marker Therapeutics, Inc. MRKR | New Enterprise Associates 16, L.P. | 1,625,678 15.200% | 554,250 (+51.73%) | Filing History |
| 2024-05-17 6:25 pm Purchase | 2024-05-15 | 13D | Marker Therapeutics, Inc. MRKR | New Enterprise Associates 16, L.P. | 1,071,428 12.000% | 1,071,428 (New Position) | Filing History |
| 2023-03-03 4:30 pm Purchase | 2021-03-16 | 13D | Marker Therapeutics, Inc. MRKR | Aisling Capital IV LP | 464,285 5.460% | 464,285 (New Position) | Filing History |
| 2021-03-26 10:38 am Purchase | 2021-03-16 | 13D | Marker Therapeutics, Inc. MRKR | New Enterprise Associates 16, L.P. | 1,446,429 17.400% | 1,446,429 (New Position) | Filing History |
| 2021-03-23 7:45 pm Sale | 2021-03-16 | 13D | Marker Therapeutics, Inc. MRKR | Leen Ann M. | 241,584 2.890% | -30,000 (-11.05%) | Filing History |
| 2021-03-15 4:45 pm Sale | 2021-03-15 | 13D | Marker Therapeutics, Inc. MRKR | Eastern Capital LTD | 396,667 5.000% | -50,000 (-11.19%) | Filing History |